9 Meters Biopharma (NMTR) Stock Forecast & Price Target

9 Meters Biopharma Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$1.70
High Forecast$1.70
Average Forecast$1.70
Low Forecast$1.70
TypeCurrent Forecast
4/24/23 to 4/23/24
1 Month Ago
3/25/23 to 3/24/24
3 Months Ago
1/24/23 to 1/24/24
1 Year Ago
4/24/22 to 4/24/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$1.70$1.70$1.70$44.18
Predicted UpsideN/A121.50% Upside121.50% Upside1,162.62% Upside
Get 9 Meters Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

NMTR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NMTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

9 Meters Biopharma Stock vs. The Competition

Type9 Meters BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside992.28% Upside10.13% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/25/2023Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/18/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$1.70+121.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:22 PM ET.

NMTR Price Target - Frequently Asked Questions

What is 9 Meters Biopharma's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for 9 Meters Biopharma stock is Hold based on the current 1 hold rating for NMTR. The average twelve-month price prediction for 9 Meters Biopharma is $1.70 with a high price target of $1.70 and a low price target of $1.70. Learn more on NMTR's analyst rating history.

Do Wall Street analysts like 9 Meters Biopharma more than its competitors?

Analysts like 9 Meters Biopharma less than other Medical companies. The consensus rating for 9 Meters Biopharma is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how NMTR compares to other companies.

Does 9 Meters Biopharma's stock price have much upside?

According to analysts, 9 Meters Biopharma's stock has a predicted upside of 121.50% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:NMTR) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners